Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo.

Slides:

Advertisements

Similar presentations

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors Iacopo Petrini, MD, Christopher A. French, MD, Arun Rajan, MD, Michael J. Cameron, MSC,

Advertisements

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Is Cytology Reliable for Epidermal Growth Factor Receptor Gene Evaluation in Non- small Cell Lung Cancer? Cecilia Bozzetti, PhD, Marcello Tiseo, MD, Costanza.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

The Signature from Messenger RNA Expression Profiling Can Predict Lymph Node Metastasis with High Accuracy for Non-small Cell Lung Cancer Naeyun Choi,

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Rafal Dziadziuszko, MD, PhD, Anh T

EGFR Status in Mesothelioma: Possible Implications for the Efficacy of Anti-EGFR and Anti-MET Therapies Sandra Salvi, PhD, Serena Varesano, PhD, Simona.

Characterization of microRNA transcriptome in tumor, adjacent, and normal tissues of lung squamous cell carcinoma Jun Wang, MD, PhD, Zhi Li, MD, PhD,

ALK FISH and IHC: You Cannot Have One without the Other

EGFR and HER2 Genomic Gain in Recurrent Non-small Cell Lung Cancer After Surgery: Impact on Outcome to Treatment with Gefitinib and Association with EGFR.

TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas

Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F

Identification and Validation of Long Noncoding RNA Biomarkers in Human Non–Small- Cell Lung Carcinomas Hui Yu, MD, Qinghua Xu, PhD, Fang Liu, PhD, Xun.

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy Sotirios Lakis,

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

A Mass Spectrometry Assay to Simultaneously Analyze ROS1 and RET Fusion Gene Expression in Non–Small-Cell Lung Cancer Priyanga Wijesinghe, PhD, Gerold.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma Erick Riquelme, PhD, Milind B. Suraokar,

Thyroid Transcription Factor-1 Amplification and Expressions in Lung Adenocarcinoma Tissues and Pleural Effusions Predict Patient Survival and Prognosis

Electronic Updates for JTO Readers

How I Do It—Optimal Methodology for Multidirectional Analysis of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples Takahiro Nakajima,

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

P16Ink4a Suppression of Lung Adenocarcinoma by Bmi-1 in the Presence of p38 Activation Mi-Ok Lee, MSc, Hyeon-Jae Lee, MD, Mi-Ae Kim, MD, Eun-Kyung Kim,

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma Lucia Anna Muscarella, PhD, Domenico Trombetta, PhD, Federico Pio.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Reliability Assurance of Detection of EML4-ALK Rearrangement in Non–Small Cell Lung Cancer: The Results of Proficiency Testing in China Yulong Li, MD,

Detection of Human Polyomavirus 7 in Human Thymic Epithelial Tumors

Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design Arnaud Uguen, MD, Pascale Marcorelles,

Christina I. Selinger, PhD, Wendy A

Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A

Increased Vascular-Endothelial Growth Factor (VEGF) Tumor Expression and Response to Epidermal Growth Factor Receptor (EGF-R) Inhibitor Erlotinib in Non-small.

MiR-205 and MiR-375 MicroRNA Assays to Distinguish Squamous Cell Carcinoma from Adenocarcinoma in Lung Cancer Biopsies Santosh Patnaik, MD, PhD, Reema.

Role of Chromosome 3q Amplification in Lung Cancer

High MET Gene Copy Number Leads to Shorter Survival in Patients with Non-small Cell Lung Cancer Heounjeong Go, MD, Yoon Kyung Jeon, MD, PhD, Hyo Jin.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

Erratum Journal of Thoracic Oncology

Mechanisms of Acquired Resistance to AZD9291

NUT Rearrangement is Uncommon in Human Thymic Epithelial Tumors

Rapid Response to Trastuzumab Emtansine in a Patient with HER2-Driven Lung Cancer Daniela Weiler, MD, Joachim Diebold, MD, Klaus Strobel, MD, Stefan.

A Novel Mechanism of EML4-ALK Rearrangement Mediated by Chromothripsis in a Patient-Derived Cell Line Tatsushi Kodama, MS, Noriko Motoi, MD, PhD, Hironori.

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Expression and Mutational Status of c-kit in Thymic Epithelial Tumors

Mitotic Inhibitors Journal of Thoracic Oncology

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity

HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers Ryoichi Onozato, MD,

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Waxing and Waning of MET Amplification in EGFR-Mutated NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure Joel P. Womack,

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

Presentation transcript:

Characterization of Fibroblast Growth Factor Receptor 1 in Small-Cell Lung Cancer Anish Thomas, MD, Jih-Hsiang Lee, MD, Zied Abdullaev, PhD, Kang-Seo Park, PhD, Marbin Pineda, PhD, Lola Saidkhodjaeva, Markku Miettinen, MD, Yisong Wang, PhD, Svetlana D. Pack, PhD, Giuseppe Giaccone, MD, PhD Journal of Thoracic Oncology Volume 9, Issue 4, Pages 567-571 (April 2014) DOI: 10.1097/JTO.0000000000000089 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 FGFR1 in SCLC cells. A, FGFR1 protein expression in SCLC cells. G, copy number gain; N, copy number normal; L, copy number loss. The numbers indicate the copy number of the FGFR1 gene determined by the real-time PCR assay. B, Correlation of FGFR1 copy number assessed by real-time PCR and mRNA expression and protein expression. C, Correlation of concentration that inhibits 50% to PD173074 and FGFR1 copy number assessed by real-time PCR assay, FGFR1 mRNA expression, or FGFR1 protein expression. FGFR1, fibroblast growth factor receptor 1; SCLC, small-cell lung cancer; PCR, polymerase chain reaction; mRNA, messenger RNA. Journal of Thoracic Oncology 2014 9, 567-571DOI: (10.1097/JTO.0000000000000089) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 FGFR1 in SCLC tumors. A, Dual-color fluorescence in situ hybridization showing FGFR1 (red fluorescence signal) gene copy number variations along with the reference chromosome 8 centromeric probe (aqua fluorescence signal) in SCLC cell lines and primary tumors. Left: Ideogram of chromosome 8 with FGFR1 gene mapped to 8p12-p11.23 chromosomal region. Normal peripheral blood lymphocytes showing two copies of FGFR1 gene on interphase and metaphase cells. B, Genome-wide frequency of copy number alterations. Gains and losses are shown in blue and red, respectively. C, High-resolution analysis showing copy number alterations in chromosome 8p where FGFR1 is located of patient samples 3 and 5 which had chromosome 8p polysomy. FGFR1, fibroblast growth factor receptor 1; SCLC, small-cell lung cancer. Journal of Thoracic Oncology 2014 9, 567-571DOI: (10.1097/JTO.0000000000000089) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions